This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (31)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Ocular/ Adnexal Tumors  • Retinal/ Chorioretinal Disorders  • Dermatology  • Melanoma  • Alert me on articles by topic

J. William Harbour, MD; Lori Worley, BS; Duanduan Ma, PhD; Michael Cohen, BS

Arch Ophthalmol. 2002;120:1341-1346.

Objective  To determine whether transducible peptides that inhibit the oncoproteins HDM2 and Bcl-2 may selectively kill uveal melanoma and retinoblastoma cells.

Methods  Peptides were tested by viability assay, flow cytometry, TUNEL (terminal deoxynucleotidyl transferase–mediated fluorescein-dUTP nick-end labeling) assay, Western blot analysis, and reverse transcription–polymerase chain reaction in cultured eye tumor cells and normal cells. Preclinical studies were performed in a rabbit xenograft model of retinoblastoma.

Main Outcome Measures  Cell survival, apoptosis, gene expression, and tumor regression.

Results  The anti–Bcl-2 peptide induced apoptosis in tumor cells, but it also caused apoptosis in normal cells in culture and induced retinal damage after intravitreal injection. In contrast, the anti-HDM2 peptide induced rapid accumulation of p53, activation of apoptotic genes, preferential killing of tumor cells, and minimal retinal damage after intravitreal injection. The anti-HDM2 peptide also induced regression of human retinoblastoma cells in rabbit eyes.

Conclusions  Peptide transduction is a promising new approach to molecular eye cancer therapy. Inhibition of HDM2 can selectively activate p53 in transformed cells and may be an effective strategy for inducing apoptosis in eye cancer cells with minimal damage to normal ocular tissues.

Clinical Relevance  Molecular characteristics of uveal melanoma and retinoblastoma may be used to design novel therapeutic agents that have greater specificity and fewer adverse effects than current therapies.

From the Department of Ophthalmology and Visual Sciences and the Division of Molecular Oncology, Washington University, St Louis, Mo.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Inhibition of Mitogen-Elicited Signal Transduction and Growth in Prostate Cancer with a Small Peptide Derived from the Functional Domain of DOC-2/DAB2 Delivered by a Unique Vehicle.
Zhou et al.
Cancer Res. 2006;66:8954-8958.
ABSTRACT | FULL TEXT  

Small Molecule Inhibition of HDM2 Leads to p53-Mediated Cell Death in Retinoblastoma Cells.
Elison et al.
Arch Ophthalmol 2006;124:1269-1275.
ABSTRACT | FULL TEXT  

Selective cell uptake of modified tat Peptide-fluorophore conjugates in rat retina in ex vivo and in vivo models.
Barnett et al.
IOVS 2006;47:2589-2595.
ABSTRACT | FULL TEXT  

Eye Cancer: Unique Insights into Oncogenesis The Cogan Lecture
Harbour
IOVS 2006;47:1737-1745.
FULL TEXT  

DDEF1 Is Located in an Amplified Region of Chromosome 8q and Is Overexpressed in Uveal Melanoma
Ehlers et al.
Clin. Cancer Res. 2005;11:3609-3613.
ABSTRACT | FULL TEXT  

Functional Analysis of the p53 Pathway in Response to Ionizing Radiation in Uveal Melanoma
Sun et al.
IOVS 2005;46:1561-1564.
ABSTRACT | FULL TEXT  

MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A
Loercher et al.
J. Cell Biol. 2005;168:35-40.
ABSTRACT | FULL TEXT  

Gene Expression Profiling in Uveal Melanoma Reveals Two Molecular Classes and Predicts Metastatic Death
Onken et al.
Cancer Res. 2004;64:7205-7209.
ABSTRACT | FULL TEXT  

Distinct Mechanisms for Regulating the Tumor Suppressor and Antiapoptotic Functions of Rb
Ma et al.
J. Biol. Chem. 2003;278:19358-19366.
ABSTRACT | FULL TEXT